In a recent article with Pharm Tech discussing how advancements in technology and a more patient-centric focus are pushing drug formulation development into exciting new directions, Asma Patel, VP, Integrated Development Services at Quotient Sciences, discusses how ML and AI allow for rapid innovation.
“From a discovery perspective, [AI and ML] can continue to fuel complexity in small new chemical and new molecular entities (NCEs/NMEs)." says Dr. Patel.
"Regardless of AI/ML, NCEs/NMEs continue to see an increase in average molecular weights and generation of new classes such as PROTACs [Proteolysis targeting chimeras], both creating solubility challenges for pharmaceutical formulation,” she adds.
“From a discovery perspective, [AI and ML] can continue to fuel complexity in small new chemical and new molecular entities (NCEs/NMEs)".
Continue reading the full article on Pharm Tech.